Guardant Health is set to drop its Q2 earnings this Thursday, riding a wave of momentum after a stellar Q1 that smashed revenue and EPS targets—with over $300M in revenue, up 48% YoY. Analysts are expecting another strong showing, projecting 35.5% YoY revenue growth, up from last year’s 30.9%. While peers like Quest and NeoGenomics posted modest gains and saw stock surges, Guardant’s shares have dipped ~8% recently, trading below its $171 average price target. The real test? Whether they can outperform expectations and reignite investor confidence ahead of the year’s final quarters.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
